XML 69 R58.htm IDEA: XBRL DOCUMENT
v3.23.3

Subsequent Event (Details) |  |  | 3 Months Ended
--- | --- | --- | ---
Nov. 03, 2023 USD ($) payment | Oct. 23, 2023 shares | Jun. 30, 2022 shares
Subsequent Event [Line Items] |  |  |
Exercise of warrants (in shares) | shares |  |  | 253,000
Subsequent Event | Clearside Biomedical, Inc. |  |  |
Subsequent Event [Line Items] |  |  |
Upfront payment | $ 5,000,000 |  |
Number of milestone payments | payment | 3 |  |
Number of royalties tiers | payment | 3 |  |
Subsequent Event | Clearside Biomedical, Inc. | Maximum |  |  |
Subsequent Event [Line Items] |  |  |
Potential milestone payment | $ 30,000,000 |  |
Potential payment if milestone reached | 47,500,000 |  |
Subsequent Event | Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million |  |  |
Subsequent Event [Line Items] |  |  |
Annual global net sales | 2,000,000,000 |  |
Subsequent Event | Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million |  |  |
Subsequent Event [Line Items] |  |  |
Annual global net sales | $ 1,500,000,000 |  |
Subsequent Event | Common Stock |  |  |
Subsequent Event [Line Items] |  |  |
Exercise of warrants (in shares) | shares |  | 14,997,000 |
Subsequent Event | Warrants to purchase common stock |  |  |
Subsequent Event [Line Items] |  |  |
Warrants outstanding (in shares) | shares |  | 0 |

X
- Definition License Agreement, Annual Global Net Sales + References No definition available. + Details
Name: | bcrx_LicenseAgreementAnnualGlobalNetSales
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Number of Milestone Payments + References No definition available. + Details
Name: | bcrx_LicenseAgreementNumberOfMilestonePayments
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Royalty Payment, Number of Tiers + References No definition available. + Details
Name: | bcrx_LicenseAgreementRoyaltyPaymentNumberOfTiers
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Upfront Payment + References No definition available. + Details
Name: | bcrx_LicenseAgreementUpfrontPayment
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Milestone Payments Payable + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsPayable
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential Milestone Payments Payable If Regulatory Approval Before Milestone + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsPayableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock Issued During Period, Shares, Warrants Exercised + References No definition available. + Details
Name: | bcrx_StockIssuedDuringPeriodSharesWarrantsExercised
Namespace Prefix: | bcrx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants or rights outstanding. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ClearsideBiomedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesOf2MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcrx_AnnualNetSalesRangeAxis=bcrx_AnnualNetSalesGreaterThan15MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |